- ICH GCP
- 欧盟临床试验注册处
最新试用
EudraCT Number: 2021-006664-24 | Sponsor Protocol Number: INVEX-CLIN-IIH-301 | Start Date: 2023-04-20 | |||||||||||
Sponsor Name: Invex Therapeutics Ltd. | |||||||||||||
Full Title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension | |||||||||||||
Medical condition: Idiopathic intracranial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004244-28 | Sponsor Protocol Number: BAN2401-G000-303 | Start Date: 2023-04-17 | |||||||||||
Sponsor Name: Eisai Ltd. | |||||||||||||
Full Title: AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Dise... | |||||||||||||
Medical condition: Preclinical Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001175-14 | Sponsor Protocol Number: BHV3000-406 | Start Date: 2023-04-17 | |||||||||||
Sponsor Name: Biohaven Pharmaceuticals, Inc. | |||||||||||||
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | |||||||||||||
Medical condition: migraine attacks with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) SE (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001876-32 | Sponsor Protocol Number: SLN360-002 | Start Date: 2023-04-14 | ||||||||||||||||
Sponsor Name: Silence Therapeutics plc | ||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at... | ||||||||||||||||||
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) SK (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000788-30 | Sponsor Protocol Number: 1.2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Uzdrowisko Kamień Pomorski S.A. | ||||||||
Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury. | ||||||||
Medical condition: | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: PL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001181-10 | Sponsor Protocol Number: P003077 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Medical Center - University of Freiburg | ||||||||
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand... | ||||||||
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ... | ||||||||
|
||||||||
Population Age: Elderly | Gender: Male, Female | |||||||
Trial protocol: AT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001393-58 | Sponsor Protocol Number: T21-118 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Hagaziekenhuis | ||||||||
Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated. | ||||||||
Medical condition: Atrial fibrillation | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001297-63 | Sponsor Protocol Number: ML-ORI-201 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Melinta Therapeutics, LLC | ||||||||
Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects... | ||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003065-38 | Sponsor Protocol Number: 1102-DMD-Pre-CT03 | Start Date: 2023-04-13 | |||||||||||
Sponsor Name: Antisense Therapeutics Limited | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002524-12 | Sponsor Protocol Number: BNZ-20-01-2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: AZAD Pharma AG | ||||||||
Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br... | ||||||||
Medical condition: GLAUCOMA , OCCULAR HYPERTENSION | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: BG (Prematurely Ended) | ||||||||
Trial results: (No results available) |